BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Urrunaga-Pastor D, Fernandez-Guzman D, Caira-Chuquineyra B, Herrera-Añazco P, Benites-Zapata VA, Bendezu-Quispe G. Prevalence and factors associated with not receiving the booster dose of the COVID-19 vaccine in adults in Latin America and the Caribbean. Travel Med Infect Dis 2022;:102409. [PMID: 35961489 DOI: 10.1016/j.tmaid.2022.102409] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Ayyalasomayajula S, Dhawan A, Karattuthodi MS, Thorakkattil SA, Abdulsalim S, Elnaem MH, Sridhar S, Unnikrishnan MK. A Systematic Review on Sociodemographic, Financial and Psychological Factors Associated with COVID-19 Vaccine Booster Hesitancy among Adult Population. Vaccines 2023;11:623. [DOI: 10.3390/vaccines11030623] [Reference Citation Analysis]
2 Al-Kassab-Córdova A, Silva-Perez C, Mendez-Guerra C, Herrera-Añazco P, Benites-Zapata VA. Factors associated with not receiving the primary series and booster dose of the COVID-19 vaccine among Venezuelan migrants in Peru: A population-based cross-sectional study. Travel Med Infect Dis 2023;53:102563. [PMID: 36898490 DOI: 10.1016/j.tmaid.2023.102563] [Reference Citation Analysis]
3 Limbu YB, Huhmann BA. Why Some People Are Hesitant to Receive COVID-19 Boosters: A Systematic Review. TropicalMed 2023;8:159. [DOI: 10.3390/tropicalmed8030159] [Reference Citation Analysis]
4 Ounsaneha W, Laosee O, Suksaroj TT, Rattanapan C. Combined Impact of Omicron Vaccination and Environmental Risk Exposure: A Thailand Case Study. Vaccines (Basel) 2023;11. [PMID: 36851174 DOI: 10.3390/vaccines11020297] [Reference Citation Analysis]
5 Solante R, Alvarez-Moreno C, Burhan E, Chariyalertsak S, Chiu NC, Chuenkitmongkol S, Dung DV, Hwang KP, Ortiz Ibarra J, Kiertiburanakul S, Kulkarni PS, Lee C, Lee PI, Lobo RC, Macias A, Nghia CH, Ong-Lim AL, Rodriguez-Morales AJ, Richtmann R, Safadi MAP, Satari HI, Thwaites G. Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. Expert Rev Vaccines 2023;22:1-16. [PMID: 36330971 DOI: 10.1080/14760584.2023.2143347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]